Ali joined SV as an Operating Partner in 2024.
Ali Jazayeri is a drug discovery expert with over 15 years of experience in company building and preclinical drug discovery in the biotech sector.
Ali was most recently Chief Scientific Officer at OMass Therapeutics, a company established by Syncona, where he led research and target strategy while contributing to the successful closure of a $100m Series B financing. Ali spearheaded the expansion of the Company’s core platform, transforming it into a fully integrated preclinical discovery engine by leveraging advanced biophysical techniques including mass spectrometry and native state technologies, to accelerate drug discovery efforts. Under his leadership, OMass’ pioneering platform delivered candidates targeting rare diseases and immunology/inflammation.
Prior to this, Ali served as Chief Technology Officer at Sosei-Heptares, where he was among the first scientists employed and became a key leader in platform development. He oversaw the integration and advancement of novel GPCR stabilization technologies from MRC Laboratory of Molecular Biology. Following the company’s acquisition by Sosei, Ali also played a central role in the acquisition of G7 Therapeutics — a spin-out from the University of Zurich — and subsequently led the integration of G7’s technologies into Heptares’ platforms. His leadership contributed to the delivery of over 15 development candidates through both internal and partnered programmes. Earlier in his career, Ali was a research scientist at KuDOS Pharmaceuticals (an SV-created company, later acquired by AstraZeneca), focusing on DNA damage response pathways.
Academic Credentials
Ali holds a BSc (Hons.) in Genetics from University of Manchester and earned his PhD in Molecular Biology from the Gurdon Institute, University of Cambridge. He conducted his post-doctoral research at Clare Hall Laboratories, a Cancer Research UK institute.
